Results 11 to 20 of about 19,884 (196)

Network analysis reveals potential markers for pediatric adrenocortical carcinoma. [PDF]

Onco Targets Ther, 2016
Pediatric adrenocortical carcinoma (ACC) is a rare malignancy with a poor outcome. Molecular mechanisms of pediatric ACC oncogenesis and advancement are not well understood.
Kulshrestha A, Suman S, Ranjan R.
europepmc   +6 more sources

Pediatric Adrenocortical Carcinoma Presenting With Virilization: A Case of a Low-Grade Tumor in a Young Child. [PDF]

Cureus
Adrenocortical carcinoma (ACC) is an uncommon and severe malignancy, particularly in the pediatric population. It often manifests with warning signs of hormonal imbalance, such as hirsutism and precocious puberty.
Askar A, Mohamed SF, Hussein Al-Mutair M.   +2 more
europepmc   +5 more sources

Targeting pediatric adrenocortical carcinoma: Molecular insights and emerging therapeutic strategies

Cancer Treatment Reviews
Pediatric adrenocortical carcinoma (pACC) is an exceptionally rare and aggressive malignancy, accounting for only 0.2-0.3% of childhood cancers. Characterized by significant endocrine activity and often associated with genetic syndromes such as Li ...
Michaela Kuhlen, Maximilian Schmutz, Marina Kunstreich   +2 more
exaly   +4 more sources

Three cases of pediatric adrenocortical carcinoma with intermediate malignant potential: a case report with literature review. [PDF]

AME Case Rep
Background Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy of the adrenal glands, characterized by a high potential for local invasion and metastasis.
Messaoud M, Alsaied A, Mosbahi S, Boukhrissa N, Sakka R, Alansari AN.   +5 more
europepmc   +4 more sources

Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. [PDF]

J Clin Oncol, 2015
Purpose Adrenocortical carcinoma (ACC) is a rare pediatric malignancy. It occurs in excess among individuals with the Li-Fraumeni syndrome, which results primarily from germline mutations in the TP53 gene. Prior series exploring frequencies of germline TP53 mutation among children with ACC have been small, geographically limited, or subject to referral
Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, Malkin D.   +6 more
europepmc   +5 more sources

Pharmacokinetic variability of mitotane in pediatric adrenocortical carcinoma and the role of CYP2B6 genotypes: a pediatric case series

EJC Paediatric Oncology
Despite therapeutic drug monitoring of mitotane, achieving target plasma concentrations remains challenging. Commonly reported enzymes involved in mitotane metabolism are cytochrome P450 (CYP)3A4 and 2B6, with CYP2B6 being highly polymorphic.
Ivy A.E. Ankone, Tirsa de Kluis, Lidwien M. Hanff, Antoinette Jaspers-Bakker, Ronald R. de Krijger, Jesse J. Swen, Kathalijne A. Oudhoff, Marieke J.M. Meijs, Max M. van Noesel, Alwin D.R. Huitema, Meta H.M. Diekstra   +10 more
doaj   +3 more sources

Mitotane-Induced Endocrine Alterations in Children with Adrenocortical Carcinoma: Clinical Implications from a 20-Year Retrospective Study [PDF]

Children
Background/Objectives: Mitotane is a key component in the treatment of adrenocortical carcinoma (ACC), but its endocrine side effects in children remain under-characterized. Methods: We conducted a retrospective analysis of 11 pediatric patients (6 males,
Gerdi Tuli, Jessica Munarin, Stefano Gabriele Vallero, Matilde Piglione, Eleonora Biasin, Luisa De Sanctis, Franca Fagioli   +6 more
doaj   +3 more sources

Treatment of Pediatric Adrenocortical Carcinoma With Surgery, Retroperitoneal Lymph Node Dissection, and Chemotherapy: The Children's Oncology Group ARAR0332 Protocol. [PDF]

J Clin Oncol, 2021
PURPOSE Adrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with distinct biology. Its treatment follows the principles developed for adults; pediatric-specific studies are scarce.
Rodriguez-Galindo C, Krailo MD, Pinto EM, Pashankar F, Weldon CB, Huang L, Caran EM, Hicks J, McCarville MB, Malkin D, Wasserman JD, de Oliveira Filho AG, LaQuaglia MP, Ward DA, Zambetti G, Mastellaro MJ, Pappo AS, Ribeiro RC.   +17 more
europepmc   +2 more sources

Establishment and characterization of the first pediatric adrenocortical carcinoma xenograft model identifies topotecan as a potential chemotherapeutic agent. [PDF]

Clin Cancer Res, 2013
Purpose: Pediatric adrenocortical carcinoma (ACC) is a rare and highly aggressive malignancy. Conventional chemotherapeutic agents have shown limited utility and are largely ineffective in treating children with advanced ACC.
Pinto EM, Morton C, Rodriguez-Galindo C, McGregor L, Davidoff AM, Mercer K, Debelenko LV, Billups C, Ribeiro RC, Zambetti GP.   +9 more
europepmc   +5 more sources

Acquired Pulmonary Arteriovenous Malformation in a Case of a Pediatric Adrenocortical Carcinoma.

Journal of the College of Physicians and Surgeons Pakistan, 2021
Null.
Rahat-Ul-Ain
semanticscholar   +4 more sources